Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases

Research output: Contribution to journalJournal articleResearchpeer-review

  1. A quantitative method for the selective 5-HT2A agonist 25CN-NBOH in rat plasma and brain

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Rapid quantification of quinine and its major metabolite (3S)-3-hydroxyquinine in diluted urine by UPLC-MS/MS

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Characterization of a liposome-based formulation of oxaliplatin using capillary electrophoresis: encapsulation and leakage

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Measurement of lumefantrine and its metabolite in plasma by high performance liquid chromatography with ultraviolet detection

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial

    Research output: Contribution to journalLetterResearchpeer-review

  2. Mutations known from B-cell lymphoid malignancies are not found in CD34+ stem cells from patients with lymphoma

    Research output: Contribution to journalLetterResearchpeer-review

  3. Clinical impact of clonal hematopoiesis in patients with lymphoma undergoing ASCT: a national population-based cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Following intense research efforts, modulation of the immune system has finally proved to be a viable approach for treating malignant disease. Recently, chimeric antigen receptor redirected T cells have achieved promising outcomes in patients with B-cell malignancies and they are currently also being investigated in other haematological malignancies, solid tumours and viral infections. Compared with traditional biopharmaceuticals, the properties of genetically modified chimeric antigen receptor redirected T-cell therapies differ in many aspects, thereby posing challenges in terms of post-authorisation data collection and data analysis. We believe that the network of population-based Nordic healthcare databases has some characteristics that can help provide important data on these new types of advanced products. In particular, the possibility of very long follow-up periods with a limited loss to follow-up is an important strength. Given the limited source population and slow access to data, a Nordic chimeric antigen receptor redirected T-cell monitoring project should be seen as complementary to other surveillance initiatives.

Original languageEnglish
JournalPharmaceutical Medicine
Volume33
Issue number2
Pages (from-to)83-88
Number of pages6
ISSN1178-2595
DOIs
Publication statusPublished - Apr 2019

ID: 59260737